Clinical trials: Type1 Diabetes
Diabetes Mellitus, Type 1
Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy
This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how Fiasp® works in a closed-loop system and to determine if any changes need to be made to the 670G pump to optimize the use of Fiasp®.
- Trial name
- NCT03554486
- Testing
- Fiasp, Novolog
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Stanford University
Type 1 Diabetes, Preservation of Insulin Secretion
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
Canakinumab is a fully human anti-interleukin-1β (anti-IL-1β) monoclonal antibody (IgG-1 class). Canakinumab is designed to bind to human IL-1β and to functionally neutralize the bioactivity of this pro-inflammatory cytokine.
- Conditions
- Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
- Trial name
- TN14 (NCT00947427)
- Testing
- canakinumab (anti IL-1beta)
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Short Sleep Phenotype, Type1diabetes
A Sleep Intervention in Type 1 Diabetes
Insufficient sleep and sleep irregularity (variability in sleep duration) are increasingly recognized as important contributors to glucose control and diabetes distress in type 1 diabetes (T1D).
- Trial name
- NCT03617770
- Testing
- Sleep Opt-In, Healthy Living
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Illinois Chicago
Diabetes Mellitus, Type 1
Isoenergetic High Intensity Interval Training and Moderate Intensity Training in Adults With Type I Diabetes
Type 1 diabetes (T1D) is associated with increased risk of poor cardiometabolic health. Regular exercise is recommended for optimal management of comorbidities in T1D.
- Trial name
- HI1T (NCT04664205)
- Testing
- High Intensity Interval Exercise, Moderate Intensity Continuous Exercise, Control
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of North Carolina, Chapel Hill
Type 1 Diabetes Mellitus
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII)…
- Trial name
- HALO-117-406 (NCT03662334)
- Testing
- Rapid Acting insulin with pre-treatment of rHuPH20
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes Mellitus
Umbilical Cord Blood Infusion to Treat Type 1 Diabetes
While this study is now completely enrolled, we do hope to develop a "next generation" cord blood based study sometime in early 2009.
- Trial name
- NCT00305344
- Testing
- Autologous Umbilical Cord Blood Transfusion, Cord blood
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Florida
Diabetes Mellitus: Type 1
A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge.
- Trial name
- NCT00662857
- Testing
- Technosphere® Insulin Inhalation Powder, Technosphere Insulin® Inhalation Powder, RAA Population
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1, Prediabetic State
Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies
The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD (Diamyd), in combination with high dose Vitamin D3, may delay or stop the autoimmune process leading to clinical type 1 diabetes in…
- Trial name
- DiAPREV-IT2 (NCT02387164)
- Testing
- Alum-GAD, Vitamin D3
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Lund University
Healthy Subjects Without Type 1 Diabetes
Continuous Glucose Sensor Profiles in Non-Diabetic Subjects
The Juvenile Diabetes Research Foundation (JDRF) Glucose Sensor Study group is carrying out a large, randomized clinical trial to assess the efficacy, safety and cost-effectiveness of use of real-time continuous glucose monitors…
- Trial name
- NCT00717977
- Testing
- Continuous glucose monitor
- Where
- 10 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Jaeb Center for Health Research
Type 1 Diabetes
Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes
The main objective is to determine the efficacy of Lyumjev (insulin) in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1.
- Trial name
- FAST 1 (NCT05508061)
- Testing
- Insulin Lispro Cartridge [Lyumjev], Insulin Lispro Cartridge
- Where
- 3 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Inreda Diabetic B.V.
Type 1 Diabetes
Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon
This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).
- Trial name
- NCT02018627
- Testing
- Xeris glucagon, Lilly glucagon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Steven J. Russell, MD, PhD
Diabetes Mellitus, Type 1
REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c 7.0%/53…
- Trial name
- REMOVAL (NCT01483560)
- Testing
- Metformin
- Where
- 24 sites in Australia, Canada and 3 more
- Volunteers
- 493 people
- Sponsor
- University of Glasgow
Diabetes Mellitus, Type 1
Immune Profile in Subjects With New Onset Type 1 Diabetes
It is hypothesized that early changes in the immune system in New Onset Type 1 Diabetes Mellitus (NOT1D) subjects can be detected in immune cells from the inguinal lymph nodes (iLN), which will be distinct from changes observed…
- Trial name
- NCT02801942
- Testing
- Inguinal lymph node fine needle aspirate biopsy, Inguinal lymph node core biopsy, Peripheral blood collection
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
Outpatient Control-to-Range: System and Monitoring Testing
A single arm, single treatment study is proposed to assess the feasibility of the AP Platform (cell phone + Control to Range system) outside of a hospital based clinical research center.
- Trial name
- NCT01578980
- Testing
- Outpatient Control-to-Range
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels.
- Trial name
- NCT01194479
- Testing
- Formoterol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yale University
Diabetes Mellitus, Insulin-Dependent
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
The objective of this clinical trial is to investigate whether ladarixin has sufficient activity (preservation of β-cell function and slow-down of the progression of T1D) to warrant its further development (proof of concept…
- Trial name
- NCT02814838
- Testing
- Ladarixin
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type1 Diabetes Mellitus
Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes
The purpose of this study is to reduce the frequency of hypoglycemia and severe hypoglycemic events in subjects who use insulin pens to treat their Type 1 Diabetes Mellitus (T1DM).
- Trial name
- DSS (NCT03093636)
- Testing
- Continuous Glucose Monitor (CGM)+Decision Support System (DSS), Continuous Glucose Monitor (CGM) alone
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Virginia
Diabetes Type 1
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.
- Trial name
- PRONTO-Pump (NCT03433677)
- Testing
- LY900014, Insulin lispro
- Where
- 5 sites in United States, Spain
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Diabetic Autonomic Neuropathy
An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes
The focus of this project is cardiovascular diabetic autonomic neuropathy (DAN). DAN affects the nerves that control heart rate and blood flow to the heart in people with diabetes.
- Trial name
- NCT00116207
- Testing
- ORAL ANTIOXIDANT
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Michigan
Type 1 Diabetes Mellitus
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this protocol is to assess the efficacy, tolerability, and safety of MGA031 when administered according to 3 different MGA031 dosing regimens in children and adults with recent-onset (diagnosis within past…
- Trial name
- NCT00385697
- Testing
- Teplizumab
- Where
- 115 sites in United States, Canada and 14 more
- Volunteers
- 554 people
- Sponsor
- MacroGenics